Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 2/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28425546 | 1.00 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22111574 | 1.00 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL23923655 | 1.00 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL23923654 | 1.00 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL20609183 | 0.83 | PSEN1 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL20609186 | 0.83 | PSEN1 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL23902357 | 0.83 | PSEN1 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18971038 | 0.83 | PSEN1 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL20031689 | 0.83 | PSEN1 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21374330 | 0.82 | APP (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326758-A1 | RICYCLIC HETEROARYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-12195470-B2 | 7-phenoxy-N-(3-azabicyclo[3.2.1]octan-8-yl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma- secretase modulators for the treatment of alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-12084461-B2 | Bicyclic heteroaryl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-4424370-A2 | 7-PHENOXY-N-(3-AZABICYCLO[3.2.1LOCTAN-8-YL)-6,7-DIHYDRO-5H-PYRROLO[1,2-B][1,2,4]TRIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | F. Hoffmann-La Roche AG (CH) | 2024-09-04 | — | — | EP | disclosed |
| EP-3894411-B1 | 7-PHENOXY-N-(3-AZABICYCLO[3.2.1]OCTAN-8-YL)-6,7-DIHYDRO-5H-PYRROLO[1,2-B][1,2,4]TRIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HOFFMANN LA ROCHE (CH) | 2024-06-19 | — | — | EP | disclosed |
| US-11370802-B2 | Triazolo-azepine derivatives | HOFFMANN-LA ROCHE, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-11370802-B2 | Triazolo-azepine derivatives | HOFFMANN-LA ROCHE, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20220056036-A1 | 7-PHENOXY-N-(3-AZABICYCLO[3.2.1]OCTAN-8-YL)-6,7-DIHYDRO-5H-PYRROLO[1,2-B][1,2,4]TRIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2022-02-24 | — | — | US | disclosed |
| EP-3743428-B1 | TRIAZOLO-AZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2022-01-19 | — | — | EP | disclosed |
| US-20210395270-A1 | TRIAZOLO-AZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210395270-A1 | TRIAZOLO-AZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210323980-A1 | BICYCLIC HETEROARYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2021-10-21 | — | — | US | disclosed |
| US-20210323980-A1 | BICYCLIC HETEROARYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12084461-B2 | Bicyclic heteroaryl derivatives | AR, CYP1B1, CYP1A1 | PSEN1 2562/4885PSEN2 2218/4885APH1B 1072/4885 |
| US-20210323980-A1 | BICYCLIC HETEROARYL DERIVATIVES | AR, CYP1B1, CYP1A1 | PSEN1 2562/4885PSEN2 2218/4885APH1B 1072/4885 |
| US-20210395270-A1 | TRIAZOLO-AZEPINE DERIVATIVES | BACE1, APP, BACE2 | PSEN1 5/4885PSEN2 8/4885APH1B 6/4885 |
| US-20220056036-A1 | 7-PHENOXY-N-(3-AZABICYCLO[3.2.1]OCTAN-8-YL)-6,7-DIHYDRO-5H-PYRROLO[1,2-B][1,2,4]TRIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, PSEN1, APP | PSEN1 2/4885PSEN2 4/4885APH1B 5/4885 |
| US-12195470-B2 | 7-phenoxy-N-(3-azabicyclo[3.2.1]octan-8-yl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma- secretase modulators for the treatment of alzheimer's disease | BACE1, PSEN1, APP | PSEN1 2/4885PSEN2 4/4885APH1B 6/4885 |
| US-11370802-B2 | Triazolo-azepine derivatives | BACE1, APP, BACE2 | PSEN1 5/4885PSEN2 8/4885APH1B 6/4885 |
| US-20250326758-A1 | RICYCLIC HETEROARYL DERIVATIVES | AR, CYP1B1, CYP1A1 | PSEN1 3060/4885PSEN2 2846/4885APH1B 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.